<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Lefèvre, Thierry</dc:creator>
  <dc:creator>Haude, Michael</dc:creator>
  <dc:creator>Neumann, Franz-Josef</dc:creator>
  <dc:creator>Stang, Karl</dc:creator>
  <dc:creator>Skurk, Carsten</dc:creator>
  <dc:creator>Slagboom, Ton</dc:creator>
  <dc:creator>Sabaté, Manel</dc:creator>
  <dc:creator>Goicolea, Javier</dc:creator>
  <dc:creator>Barragan, Paul</dc:creator>
  <dc:creator>Cook, Stéphane</dc:creator>
  <dc:creator>Macia, Jean-Christophe</dc:creator>
  <dc:creator>Windecker, Stephan</dc:creator>
  <dc:date>2018-05-28</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">ObjectivesThe authors aimed to compare long-term data of an ultrathin cobalt- chromium stent with passive silicon carbide coating and an active biodegradable  polymer that releases sirolimus (O-SES) (Orsiro, BIOTRONIK, Bülach, Switzerland)  with the durable polymer-based Xience Prime everolimus-eluting stent (X-EES)  (Abbott Vascular, Santa Clara, California).BackgroundBiodegradable polymer stents  have been developed aiming to overcome long-term detrimental effects of durable  polymer stents, ultimately leaving a bare-metal stent in the vessel.MethodsThis  multicenter, assessor-blinded trial randomized 452 patients with 505 lesions to either  O-SES or X-EES in a 2:1 fashion. Endpoints at 5 years were target lesion failure  (TLF), its components, and stent thrombosis.ResultsTLF occurred in 10.4% (n = 30) of  O-SES patients versus 12.7% (n = 19) of X-EES patients (p = 0.473), overall stent  thrombosis occurred in 0.7% (n = 2) versus 2.8% (n = 4) (p = 0.088), and definite stent  thrombosis in 0% versus 0.7% (n = 1) (p = 0.341). Post hoc analysis was performed in  diabetic patients (n = 128) and vessels ≤2.75 mm (n = 259). In diabetic patients, the  O-SES group had numerically more target lesion revascularizations (13.5% vs. 4.5%;  p = 0.138), but fewer cardiac deaths (1.3% vs. 6.9%; p = 0.089) and stent thrombosis  (0% vs. 6.9%; p = 0.039). In small vessels, the O-SES group had a significantly lower  5-year mortality (3.7% vs. 11.3%; p = 0.022).ConclusionsAt 5 years, the  biodegradable polymer O-SES demonstrated low TLF rates comparable to the  durable polymer X-EES, confirming its long-term safety and performance. Particularly  encouraging is the absence of definite stent thrombosis.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/307127</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307127/files/coo_cnb.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jcin.2018.04.014</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>JACC: Cardiovascular Interventions. - 2018, vol. 11, no. 10, p. 995–1002</dc:source>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized bioflow-ii trial</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
